1887

Abstract

The L1 gene of human papillomavirus type 16 (HPV- 16) driven by the vaccinia virus major late 4b gene promoter has been inserted into three different sites of the vaccinia virus genome. Insertion into the thymidine kinase (TK) gene was achieved by selection of TK mutants in BUdR on TK cells. Insertion into two vaccinia virus serine protease inhibitor (serpin) genes was achieved by co-insertion of the xanthine guanine phosphoribosyltransferase gene linked to the vaccinia virus 7·5K promoter and selection of mycophenolic acid-resistant recombinant viruses. Each recombinant virus expressed a 57K L1 protein at similar levels and with similar kinetics. However, immunization of mice with these recombinant viruses induced different levels of antibody to the LI protein. Viruses lacking serpin genes B13R and B24R induced significantly higher antibody levels than did viruses lacking the TK gene. The presence of functional B13R and B24R gene products is therefore somehow immunosuppressive at least for antibody responses to the LI protein of HPV-16.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-71-9-2185
1990-09-01
2023-02-05
Loading full text...

Full text loading...

/deliver/fulltext/jgv/71/9/JV0710092185.html?itemId=/content/journal/jgv/10.1099/0022-1317-71-9-2185&mimeType=html&fmt=ahah

References

  1. Bennink J. R., Yewdell J. W., Smith G. L., Moller C., Moss B. 1984; Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature; London: 311578–579
    [Google Scholar]
  2. Bennink J. R., Yewdell J. W., Smith G. L., Moss B. 1986; Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. Journal of Virology 57:786–791
    [Google Scholar]
  3. Boursnell M. E. G., Foulds I. J., Campbell J. I., Binns M. M. 1988; Non-essential genes in the vaccinia virus HindIII K fragment: a gene related to serine protease inhibitors and a gene related to the 37K vaccinia virus major envelope antigen. Journal of General Virology 69:2995–3003
    [Google Scholar]
  4. Boyle D. B., Coupar E. H. 1988; A dominant selectable marker for construction of recombinant poxviruses. Gene 65:123–128
    [Google Scholar]
  5. Browne H. M., Churcher M. J., Stanley M. A., Smith G. L., Minson A. C. 1988; Analysis of the LI gene product of human papillomavirus type 16 by expression in a vaccinia virus recombinant. Journal of General Virology 69:1263–1273
    [Google Scholar]
  6. Buller R. M. L., Smith G. L., Cremer K., Notkins A. L., Moss B. 1985; Decreased virulence of recombinant vaccinia virus expression vectors is associated with a TK-negative phenotype. Nature; London: 317812–815
    [Google Scholar]
  7. Chua T. P., Smith C. E., Reith R. W., Williamson J. D. 1990; Inflammatory responses and the generation of chemoattractant activity in cowpox virus-infected tissues. Immunology 69:202–208
    [Google Scholar]
  8. Coupar B. E. H., Andrew M. E., Both G. W., Boyle D. B. 1986; Temporal regulation of influenza haemagglutinin expression in vaccinia virus recombinants and effects on the immune response. European Journal of Immunology 16:1479–1487
    [Google Scholar]
  9. Cremer K., Mackett M., Wohlenberg G., Notkins A. L., Moss B. 1985; Vaccinia virus recombinants expressing herpes simplex virus type 1 glycoprotein D prevent latent herpes in mice. Science 228:737–740
    [Google Scholar]
  10. Dürst M., Gissmann L., Ikenburg H., zur Hausen H. 1983; A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proceedings of the National Academy of Sciences, U.S.A 80:3812–3815
    [Google Scholar]
  11. Dürst M., Kleinheinz A., Hotz M., Gissmann L. 1985; The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. Journal of General Virology 66:1515–1522
    [Google Scholar]
  12. Falkner F. G., Moss B. 1988; Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. Journal of Virology 62:1849–1854
    [Google Scholar]
  13. Gould K., Gossins J., Bastin J., Brownlee G. G., Townsend A. R. M. 1989; A 15 amino acid fragment of influenza virus nucleoprotein synthesised in the cytoplasm is presented to class 1-restricted cytotoxic T lymphocytes. Journal of Experimental Medicine 170:1051–1056
    [Google Scholar]
  14. Kent R. K. 1988 The isolation and analysis of the vaccinia virus 4b promoter Ph.D. thesis University of Cambridge:
    [Google Scholar]
  15. Kotwal G. J., Moss B. 1989; Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily. Journal of Virology 63:600–606
    [Google Scholar]
  16. Lathe R., Kieny M. P., Gerlinger P., Clertant P., Guizanik I., Cuzin F., Chambon P. 1987; Tumor prevention and rejection with recombinant vaccinia virus. Nature; London: 326878–880
    [Google Scholar]
  17. Mackett M., Arrand J. R. 1985; Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO Journal 4:3229–3234
    [Google Scholar]
  18. Mackett M., Smith G. L., Moss B. 1984; General method for the production and selection of vaccinia virus recombinants expressing foreign genes. Journal of Virology 49:857–864
    [Google Scholar]
  19. Mackett M., Smith G. L., Moss B. 1985a; The construction and characterization of vaccinia virus recombinants expressing foreign genes. In DNA Cloning: A Practical Approach 2 pp. 191–211 Glover D. M. Edited by Oxford: IRL Press;
    [Google Scholar]
  20. Mackett M., Yilma T., Rose J., Moss B. 1985b; Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 227:422–435
    [Google Scholar]
  21. Mclean C. S., Churcher M. J., Meinke J., Smith G. L., Higgins G., Stanley M., Minson A. C. 1990; Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using a recombinant vaccinia virus. Journal of Clinical Pathology 43:488–492
    [Google Scholar]
  22. Mcmichael A. J., Michie C. A., Gotch F. M., Smith G. L., Moss B. 1986; Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. Journal of General Virology 67:719–726
    [Google Scholar]
  23. Moss B., Smith G. L., Gerin J. L., Purcell R. H. 1984; Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature; London: 31167–69
    [Google Scholar]
  24. Palumbo G. J., Pickup D. J., Fredrickson T. N., Mcintyre L. J., Buller R. M. L. 1989; Inhibition of an inflammatory response is mediated by a 38-kDa protein of cowpox virus. Virology 172:262–273
    [Google Scholar]
  25. Paoletti E., Lipinskas B. R., Samsonoff C., Mercer S., Panicali D. 1984; Construction of live vaccinia viruses using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proceedings of the National Academy of Sciences, U.S.A 81:193–197
    [Google Scholar]
  26. Pickup D. J., Ink B. S., Hu W., Ray C. A., Joklik W. K. 1986; Hemorrhage in lesions caused by cowpox virus is inhibited by a viral protein that is related to plasma protein inhibitors of serine proteases. Proceedings of the National Academy of Sciences, U.S.A 83:7698–7702
    [Google Scholar]
  27. Pilacinski W. P., Glassman D. L., Glassman K. F., Reed D. V., Lum M. A., Marshall R., Muscoplat C. C., Faras A. J. 1985; Immunization against bovine papillomavirus infection. In Ciba Foundation Symposium 120 pp. 136–156 Evered D., Clark S. Edited by London: Ciba Foundation;
    [Google Scholar]
  28. Rohrmann G., Yuen L., Moss B. 1986; Transcription of vaccinia virus early genes by enzymes isolated from vaccinia virions terminates downstream of a regulatory sequence. Cell 46:1029–1035
    [Google Scholar]
  29. Rosel J., Moss B. 1985; Transcriptional and translational mapping and nucleotide sequence of a vaccinia virus gene encoding the precursor of the major core polypeptide 4b. Journal of Virology 56:830–838
    [Google Scholar]
  30. Seedorf K., Krammer G., Dürst M., Suhai S., Rowekamp W. G. 1985; Human papillomavirus type 16 DNA sequence. Virology 145:181–185
    [Google Scholar]
  31. Smith G. L., Mackett M., Moss B. 1983a; Infectious vaccinia virus recombinants expressing hepatitis B virus surface antigen. Nature; London: 302490–495
    [Google Scholar]
  32. Smith G. L., Murphy B. R., Moss B. 1983b; Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza virus hemagglutinin and induces resistance to influenza virus infection in hamsters. Proceedings of the National Academy of Sciences, U.S.A 80:7155–7159
    [Google Scholar]
  33. Smith G. L., Howard S. T., Chan Y. S. 1989; Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. Journal of General Virology 70:2333–2343
    [Google Scholar]
  34. Townsend A. R. M., Bastin J., Gould K., Brownlee G. G., Andrew A., Boyle D. B., Chan Y. S., Smith G. L. 1988; Defective presentation to class I restricted CTL in vaccinia infected cells is overcome by enhanced degradation of antigen. Journal of Experimental Medicine 168:1211–1224
    [Google Scholar]
  35. Wiktor J. J., Macfarlan R. I., Reagan K. H., Dietzschold B., Curtis P. J., Wunner W. H., Kieny M. P., Lathe R., Lecocq J. P., Mackett M., Moss B., Koprowski H. 1984; Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proceedings of the National Academy of Sciences, U.S.A 81:7194–7198
    [Google Scholar]
  36. Yewdell J. W., Bennink J. R., Smith G. L., Moss B. 1985; Influenza A virus nucleoprotein is a major target antigen for cross reactive anti-influenza A virus cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences, U.S.A 82:1785–1789
    [Google Scholar]
  37. Yuen L., Moss B. 1987; Oligonucleotide sequence signalling transcriptional termination of vaccinia virus early genes. Proceedings of the National Academy of Sciences, U.S.A 84:6417–6421
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-71-9-2185
Loading
/content/journal/jgv/10.1099/0022-1317-71-9-2185
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error